Be sure to attend ASM Microbe talks by Pattern CEO, Carey-Ann Burnham. Learn more about the future of clinical microbiology and Pattern's Pneumonia ID/AST test. Visit us at Booth #1209.
Pattern Bioscience
Biotechnology Research
Austin, Texas 5,942 followers
Our mission is simple: We will improve the world's most important health decisions.
About us
Tackling a global health threat like antimicrobial resistance is not for the faint of heart, but the experienced and innovative team at Pattern Bioscience is on a mission to do it. Each year, drug-resistant bacterial infections claim more than a million lives globally and cost our healthcare system billions of dollars. Traditional diagnostic methods for bacterial infections remain rooted in slow, cumbersome, decades-old technology that contributes to sub-optimal treatment and the misuse of broad-spectrum antibiotics. The Pattern system is different. We’re developing the world’s only culture-free, rapid diagnostic technology that will reduce the time needed for pathogen identification (ID) and antibiotic susceptibility test (AST) results from days to hours. Our technology combines single-cell analysis of microorganisms with machine learning tools to deliver fast, clinically actionable information. The result? Patients get the right treatment faster, to save lives, prevent side effects and reduce healthcare costs.
- Website
-
https://pattern.bio
External link for Pattern Bioscience
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Austin, Texas
- Type
- Privately Held
- Founded
- 2016
Locations
-
Primary
Get directions
Austin, Texas 78759, US
Employees at Pattern Bioscience
Updates
-
Pattern Bioscience has surpassed 1,000 samples in our multi-center U.S. clinical trial of a rapid, direct-from-specimen pneumonia ID/AST panel, marking the halfway point of the study designed to support our FDA 510(k) submission. For critically ill pneumonia patients, clinicians often wait 2–4 days for culture-based susceptibility results. That delay impacts therapy decisions, ICU length of stay, and patient outcomes. Our single-cell microbiology platform is designed to address this gap, delivering pathogen ID and phenotypic AST results in hours, directly from respiratory specimens. Learn more: https://lnkd.in/gfkb24pX
-
We're proud to announce a $43 million Series D financing raise, in partnership with AMR Action Fund, Illumina Ventures, and Omnimed Capital. The funding brings us closer to our mission of transforming how bacterial infections are diagnosed and treated by supporting the completion of a U.S. multi-center clinical trial and the pursuit of FDA clearance for our rapid Pneumonia ID/AST Panel. More details: https://lnkd.in/ecndh2Qy
-
A huge thank you to everyone who engaged with us at our booth, attended our Spotlight Talk, and explored our posters at ASM Microbe 2025. We appreciated the opportunity to share how our single-cell platform has the potential to reshape clinical microbiology, and to connect with so many innovators working to move infectious disease diagnostics forward.
-
-
We’ll be at ASM Microbe 2025 in Los Angeles next week! Join us for live demos at Booth #2131 and explore four posters featuring data on rapid testing across three different sample types. Don’t miss our Spotlight Talk at 3:15 PM on Friday, June 20 in Lounge n’ Learn 3, where we’ll present new preclinical data.
-
We’re headed to ASM Microbe 2025 in Los Angeles, and we can’t wait to share what we’ve been working on. Connect with us at Booth #2131 to see how our single-cell microbiology platform is redefining how we detect and treat infectious diseases. From faster antibiotic susceptibility testing to deeper cellular insights, we're driving microbiology forward.
-